A rational two-step approach to KRAS mutation testing in colorectal cancer using high resolution melting analysis and pyrosequencing

BACKGROUND: KRAS mutation testing is mandatory in the management of metastatic colorectal cancer prior to treatment with anti-EGFR antibodies as patients whose tumors express mutant KRAS do not benefit from these agents. Although the U.S. Food and Drug Administration has recently approved two in-vit...

Descripción completa

Detalles Bibliográficos
Autores principales: Mack, Elisabeth, Stabla, Kathleen, Riera-Knorrenschild, Jorge, Moll, Roland, Neubauer, Andreas, Brendel, Cornelia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4971616/
https://www.ncbi.nlm.nih.gov/pubmed/27485514
http://dx.doi.org/10.1186/s12885-016-2589-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4971616/
https://www.ncbi.nlm.nih.gov/pubmed/27485514
http://dx.doi.org/10.1186/s12885-016-2589-2

Ejemplares similares